Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Environmental Panels as a Proxy for Nursing Facility Patients With Methicillin-Resistant Staphylococcus Aure and Vancomycin-Resistant Enterococcus Colonization.

Cassone M, Mantey J, Perri MB, Gibson K, Lansing B, McNamara S, Patel PK, Cheng VCC, Walters MS, Stone ND, Zervos MJ, Mody L.

Clin Infect Dis. 2018 May 2. doi: 10.1093/cid/ciy115. [Epub ahead of print]

PMID:
29726892
2.

Longitudinal Assessment of Multidrug-Resistant Organisms in Newly Admitted Nursing Facility Patients: Implications for an Evolving Population.

Mody L, Foxman B, Bradley S, McNamara S, Lansing B, Gibson K, Cassone M, Armbruster C, Mantey J, Min L.

Clin Infect Dis. 2018 Apr 9. doi: 10.1093/cid/ciy194. [Epub ahead of print]

PMID:
29635360
3.

Targeted Next Generation Sequencing in patients with Myotonia Congenita.

Ferradini V, Cassone M, Nuovo S, Bagni I, D'Apice MR, Botta A, Novelli G, Sangiuolo F.

Clin Chim Acta. 2017 Jul;470:1-7. doi: 10.1016/j.cca.2017.04.012. Epub 2017 Apr 17.

PMID:
28427807
4.

Genotype-phenotype correlation of F484L mutation in three Italian families with Thomsen myotonia.

Cassone M, Ferradini V, Longo G, Sarchielli P, Murasecco D, Romoli M, Pasquini E, Novelli G, Prontera P, Sangiuolo F.

Muscle Nerve. 2017 Jun;55(6):E24-E25. doi: 10.1002/mus.25407. Epub 2017 Mar 26. No abstract available.

PMID:
27639085
5.

Infection Control in Alternative Health Care Settings: An Update.

Flanagan E, Cassone M, Montoya A, Mody L.

Infect Dis Clin North Am. 2016 Sep;30(3):785-804. doi: 10.1016/j.idc.2016.05.001. Review.

6.

Infections in Nursing Homes: Epidemiology and Prevention Programs.

Montoya A, Cassone M, Mody L.

Clin Geriatr Med. 2016 Aug;32(3):585-607. doi: 10.1016/j.cger.2016.02.004. Review.

PMID:
27394025
7.

Impact of Intervention Measures on MRSA Clonal Type and Carriage Site Prevalence.

Cassone M, McNamara SE, Perri MB, Zervos M, Mody L.

MBio. 2016 Mar 8;7(2):e00218. doi: 10.1128/mBio.00218-16. No abstract available.

8.

A new case of prenatally diagnosed pentasomy x: review of the literature.

Pirollo LM, Salehi LB, Sarta S, Cassone M, Capogna MV, Piccione E, Novelli G, Pietropolli A.

Case Rep Obstet Gynecol. 2015;2015:935202. doi: 10.1155/2015/935202. Epub 2015 Jan 29.

9.
10.

Methicillin-resistant Staphylococcus aureus: site of acquisition and strain variation in high-risk nursing home residents with indwelling devices.

Gibson KE, McNamara SE, Cassone M, Perri MB, Zervos M, Mody L; Targeted Infection Prevention Study Team, Ann Arbor, Michigan.

Infect Control Hosp Epidemiol. 2014 Dec;35(12):1458-65. doi: 10.1086/678599. Epub 2014 Nov 5.

11.

Hydroxyproline substitutions stabilize non-glycosylated drosocin against serum proteases without challenging its antibacterial activity.

Knappe D, Cassone M, Nollmann FI, Otvos L, Hoffmann R.

Protein Pept Lett. 2014 Apr;21(4):321-9.

PMID:
24164265
12.

Competence in Streptococcus pneumoniae is a response to an increasing mutational burden.

Gagne AL, Stevens KE, Cassone M, Pujari A, Abiola OE, Chang DJ, Sebert ME.

PLoS One. 2013 Aug 13;8(8):e72613. doi: 10.1371/journal.pone.0072613. eCollection 2013.

13.

The HtrA protease from Streptococcus pneumoniae digests both denatured proteins and the competence-stimulating peptide.

Cassone M, Gagne AL, Spruce LA, Seeholzer SH, Sebert ME.

J Biol Chem. 2012 Nov 9;287(46):38449-59. doi: 10.1074/jbc.M112.391482. Epub 2012 Sep 25.

14.

Design and development of a peptide-based adiponectin receptor agonist for cancer treatment.

Otvos L Jr, Haspinger E, La Russa F, Maspero F, Graziano P, Kovalszky I, Lovas S, Nama K, Hoffmann R, Knappe D, Cassone M, Wade J, Surmacz E.

BMC Biotechnol. 2011 Oct 5;11:90. doi: 10.1186/1472-6750-11-90.

15.

Broad-spectrum antimicrobial efficacy of peptide A3-APO in mouse models of multidrug-resistant wound and lung infections cannot be explained by in vitro activity against the pathogens involved.

Ostorhazi E, Holub MC, Rozgonyi F, Harmos F, Cassone M, Wade JD, Otvos L Jr.

Int J Antimicrob Agents. 2011 May;37(5):480-4. doi: 10.1016/j.ijantimicag.2011.01.003. Epub 2011 Feb 24.

PMID:
21353493
16.

Preclinical advantages of intramuscularly administered peptide A3-APO over existing therapies in Acinetobacter baumannii wound infections.

Ostorhazi E, Rozgonyi F, Sztodola A, Harmos F, Kovalszky I, Szabo D, Knappe D, Hoffmann R, Cassone M, Wade JD, Bonomo RA, Otvos L Jr.

J Antimicrob Chemother. 2010 Nov;65(11):2416-22. doi: 10.1093/jac/dkq337. Epub 2010 Sep 1.

17.

Intramuscularly administered peptide A3-APO is effective against carbapenem-resistant Acinetobacter baumannii in mouse models of systemic infections.

Ostorhazi E, Rozgonyi F, Szabo D, Binas A, Cassone M, Wade JD, Nolte O, Bethel CR, Bonomo RA, Otvos L Jr.

Biopolymers. 2011;96(2):126-9. doi: 10.1002/bip.21443.

18.

Peptide-based leptin receptor antagonists for cancer treatment and appetite regulation.

Otvos L Jr, Kovalszky I, Scolaro L, Sztodola A, Olah J, Cassone M, Knappe D, Hoffmann R, Lovas S, Hatfield MP, Beko G, Zhang S, Wade JD, Surmacz E.

Biopolymers. 2011;96(2):117-25. doi: 10.1002/bip.21377.

PMID:
20564005
19.

Synergy among antibacterial peptides and between peptides and small-molecule antibiotics.

Cassone M, Otvos L Jr.

Expert Rev Anti Infect Ther. 2010 Jun;8(6):703-16. doi: 10.1586/eri.10.38. Review.

PMID:
20521897
20.

The designer proline-rich antibacterial peptide A3-APO is effective against systemic Escherichia coli infections in different mouse models.

Szabo D, Ostorhazi E, Binas A, Rozgonyi F, Kocsis B, Cassone M, Wade JD, Nolte O, Otvos L Jr.

Int J Antimicrob Agents. 2010 Apr;35(4):357-61. doi: 10.1016/j.ijantimicag.2009.10.015. Epub 2009 Dec 23.

PMID:
20031377

Supplemental Content

Loading ...
Support Center